Patents Face 'Real Threat' From Inter Partes Review; PTAB Open To Change
Executive Summary
Pfizer attorney says brand-name drug companies no longer can rely on the outcome of ANDA litigation to predict date of generic competition; PTAB chief judge observes that there is 'opportunity to get some more certainty for patent owners.'